These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25641178)

  • 1. Osteoprotegerin is up-regulated in pancreatic cancers and correlates with cancer-associated new-onset diabetes.
    Shi W; Qiu W; Wang W; Zhou X; Zhong X; Tian G; Deng A
    Biosci Trends; 2014 Dec; 8(6):322-6. PubMed ID: 25641178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.
    Secchiero P; Corallini F; Pandolfi A; Consoli A; Candido R; Fabris B; Celeghini C; Capitani S; Zauli G
    Am J Pathol; 2006 Dec; 169(6):2236-44. PubMed ID: 17148684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles.
    Huang H; Dong X; Kang MX; Xu B; Chen Y; Zhang B; Chen J; Xie QP; Wu YL
    Am J Gastroenterol; 2010 Jul; 105(7):1661-9. PubMed ID: 20571492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.
    Tavintharan S; Pek LT; Liu JJ; Ng XW; Yeoh LY; Su Chi L; Chee Fang S
    Diab Vasc Dis Res; 2014 Sep; 11(5):359-62. PubMed ID: 25005034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
    Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
    Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.
    Nybo M; Poulsen MK; Grauslund J; Henriksen JE; Rasmussen LM
    Diabet Med; 2010 Mar; 27(3):289-94. PubMed ID: 20536491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
    Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
    Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk.
    Davenport C; Ashley DT; O'Sullivan EP; Corley BT; Fitzgerald P; Agha A; Thompson CJ; O'Gorman DJ; Smith D
    J Hypertens; 2011 Dec; 29(12):2469-75. PubMed ID: 21970938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of osteoprotegerin expression in human colorectal cancer.
    Tsukamoto S; Ishikawa T; Iida S; Ishiguro M; Mogushi K; Mizushima H; Uetake H; Tanaka H; Sugihara K
    Clin Cancer Res; 2011 Apr; 17(8):2444-50. PubMed ID: 21270110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes.
    Blázquez-Medela AM; García-Ortiz L; Gómez-Marcos MA; Recio-Rodriguez JI; Sánchez-Rodríguez A; López-Novoa JM; Martínez-Salgado C
    Eur J Clin Invest; 2012 May; 42(5):548-56. PubMed ID: 22050177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
    Martinetti A; Bajetta E; Ferrari L; Zilembo N; Seregni E; Del Vecchio M; Longarini R; La Torre I; Toffolatti L; Paleari D; Bombardieri E
    Endocr Relat Cancer; 2004 Dec; 11(4):771-9. PubMed ID: 15613451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.
    Terekeci HM; Senol MG; Top C; Sahan B; Celik S; Sayan O; Kucukardali Y; Ipcioglu O; Cagiltay E; Oktenli C; Ozata M
    Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):119-23. PubMed ID: 19053023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.
    Cai CY; Zhai LL; Wu Y; Tang ZG
    Eur J Surg Oncol; 2015 Feb; 41(2):228-35. PubMed ID: 25434328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
    Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
    Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.
    Koo HM; Do HM; Kim EJ; Lee MJ; Shin DH; Kim SJ; Oh HJ; Yoo DE; Kim JK; Park JT; Han SH; Kang SW; Choi KH; Yoo TH
    Atherosclerosis; 2011 Dec; 219(2):925-30. PubMed ID: 22015178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational prediction and experimental validation associating FABP-1 and pancreatic adenocarcinoma with diabetes.
    Sharaf RN; Butte AJ; Montgomery KD; Pai R; Dudley JT; Pasricha PJ
    BMC Gastroenterol; 2011 Jan; 11():5. PubMed ID: 21251264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
    Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin, leptin and IL-6: association with silent myocardial ischemia in type 2 diabetes mellitus.
    Guzel S; Seven A; Kocaoglu A; Ilk B; Guzel EC; Saracoglu GV; Celebi A
    Diab Vasc Dis Res; 2013 Jan; 10(1):25-31. PubMed ID: 22496403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.